The trial aims to investigate each patient for toxicity, biochemical (Prostate Specific Antigen), radiographic and clinical responses.
Previosly, APC-100 has been shown to have higher therapeutic activity than the current marketed Standard of Care anti-androgens.
Adamis president and CEO Dennis Carlo said moving APC-100 into human clinical trials is yet another major milestone for the company.
"Because of its mechanism of action, APC-100 can be used either as a stand-alone treatment or be used to enhance the activity of existing or upcoming new anti-prostate cancer products," Carlo said.